Search

According to the recommendations of the European Society of Cardiology (ESC) 2021 for the management of patients with chronic heart failure (CHF), it is necessary to take into account the iron level in the diagnosis of all patients with firstly diagnosed heart failure (HF). Also the practical recommendations indicate that the assessment of iron deficiency is also carried out in patients with already confirmed CHF, especially if the symptoms of HF persist against the background of optimal treatment of the underlying disease, which necessitates knowledge of the diagnosis of anemia and iron deficiency in patients with CHF. The aim was review literature illustrating current data about diagnostics of iron deficiency and anemia in patients with CHF. In the work 28 sources from the Web of Science database and 7 sources from the PubMed database were analyzed. Anemia is diagnosed by hemoglobin levels. As criteria for iron deficiency, two parameters are used in clinical practice – ferritin level and transferrin saturation. The mean corpuscular volume of erythrocytes and the mean hemoglobin content in them were not reliable markers of iron deficiency and are not recommended for assessing iron deficiency in patients with HF. Depletion of iron stores in the bone marrow is a highly specific for iron deficiency, as it is not affected by inflammation and therefore the test for iron stores in the bone marrow is the gold standard for diagnosis, however its use in clinical practice is limited due to invasiveness and high cost. Diagnostic markers such as levels of hepsidin, dissolved transferrin receptor and ferritin index have low availability in laboratories. Since timely diagnosis followed by treatment of anemia and iron deficiency in patients with CHF impoves the quality of life of patients, therefore, increasing the diagnostic value of tests to identify iron deficiency remains a question for active research. [ABSTRACT FROM AUTHOR]

The purpose of the study was to establish clinical features of permanent atrial fibrillation (AF) in patients with heart failure mid-range ejection fraction (HFmrEF) and to develop a mathematical model for predicting arrhythmia development. The study included 42 patients with IHD, arterial hypertension (AH), permanent AF and HFmrEF (1 group), mean age – 68.0±1.2 years (21 men and 21 women) and 36 patients with CAD / АH and HFmrEF without AF, mean age-67.5±0.7 years (22 men and 14 women). The results of the study show, that patients with permanent AF and HFmrEF are characterized by the higher diastolic arterial pressure, higher values of the LDLP, iESV LV, index of end-systolic volume of LV septal thickness and lower EF of the LV in comparison with patients without AF. Patients with permanent AF and HFmrEF also have increased plasma levels of hsCRP, IL-1β, IL-6 and IL-10 in comparison with patients without AF. A mathematical model with scoring system of hsCRP, IL-1β, LV mass index, HDLP, LDLP was developed to assess the risk of AF development in patients with HFmrEF with accuracy of 85.9%, sensitivity of 85.7% and specificity of 86.1%. [ABSTRACT FROM AUTHOR]

ATP-sensitive potassium channels (KATP-channels) have an exclusive cardioprotective role in endogenous heart protection from ischemic damage and regulate vascular tone. KCNJ11 (Kir6.2) polymorphisms I337V (rs5215) and G23L (rs5219, E23K), and ABCC8 (SUR1) polymorphisms S1369A (rs757110) was genotyped in 529 patients with myocardial infarction, acute and chronic heart failure, in adolescents with primary hypertension, and as control group in clinically healthy subjects of Ukraine population by the real-time polymerase chain reaction (RT-PCR). It was shown that the frequency of genotypes Glu/Glu, Glu/Lys and Lys/Lys of polymorphism E23K, and genotypes Ser/Ser, Ser/Ala and Ala/Ala of polymorphism S1369A was as follows: in 107 patients with myocardial infarction - 40.2, 43.9 and 15.9%; in 96 patients with acute heart failure - 41.7, 42.7 and 15.6%; in 99 patients with chronic heart failure - 43.4, 44.4 and 12.1%; in 104 adolescents with primary hypertension - 41.4, 46.2 and 12.5% respectively. The distribution of these genotypes in the control group in 98 clinically healthy people was 37.8, 46.9 and 15.3% respectively. Inheritance of SNPs E23K and S1369A were linked. The frequency of genotypes Ile/Ile, Ile/Val and Val/Val of polymorphism I337V was as follows: in 102 patients with myocardial infarction - 32.4, 51.0 and 16.7%; in 93 patients with acute heart failure - 37,6, 43,0 and 19,4%; in 98 patients with chronic heart failure - 40,8, 44,9 and 14,3%; in 90 clinically healthy people - 35.6, 45.6 and 18.9% respectively. Incidence of allelic polymorphisms I337V, E23K and S1369A corresponds to Hardy-Weinberg principle. By criterion χ², no significant differences were found between the groups. Thus, the frequency of allele polymorphisms I337V, E23K, and S1369A in patients with myocardial infarction, acute and chronic heart failure, and primary hypertension in adolescents was determined, and it has been shown that it does not significantly differ from the frequency in clinically healthy residents of Ukraine. [ABSTRACT FROM AUTHOR]